Travel Vaccines Market Synopsis

Global Travel Vaccines Market size was valued at USD 10.98 billion in 2022 and is projected to reach USD 21.64 Billion by 2030, growing at a CAGR of 8.85% from 2023 to 2030.

• Travel vaccines, also known as travel immunizations or travel vaccinations, are vaccinations that individuals receive before traveling to certain regions or countries to protect them from specific diseases that may be prevalent in those areas. The goal is to prevent the spread of infectious diseases and protect both travellers and the local population.
• The specific vaccines recommended or required for travel depend on various factors, including the destination, the duration of the trip, the traveller’s age, health status, and previous immunization history.
• The necessity for travel vaccines arises because different regions of the world may have unique health risks and endemic diseases that are not prevalent in the traveller’s home country. Exposure to these diseases can lead to illness or infection, and in some cases, these diseases may have severe consequences.
• Common travel vaccines protect against diseases such as yellow fever, typhoid, hepatitis A and B, meningitis, polio, Japanese encephalitis, rabies, and influenza. The choice of vaccines depends on various factors, including the traveller’s destination, the duration of stay, planned activities, and individual health considerations.
• Many countries require proof of specific vaccinations as a condition of entry. For example, some nations in Africa and South America may require proof of yellow fever vaccination, while others in Asia may demand evidence of protection against Japanese encephalitis.

The Travel Vaccines Market Trend Analysis

Disease Exposure in Specific Regions

• Disease exposure in specific regions stands as a compelling driver for the necessity of travel vaccines. When individuals travel to different parts of the world, they may encounter infectious diseases that are not prevalent in their home countries. Regions with tropical climates, for instance, may pose risks of diseases such as malaria, dengue fever, and Zika virus, which might be uncommon or non-existent in temperate zones. Waterborne infections like cholera are also more prevalent in certain areas, presenting a health risk to travellers who may not have developed immunity to these region-specific pathogens.
• The varying prevalence of diseases across the globe underscores the importance of tailored immunization. Travel vaccines provide a proactive defense against the unique health challenges posed by different regions, ensuring that individuals are equipped with the necessary antibodies to combat specific pathogens they may encounter during their journeys. This approach not only protects the health of the travellers but also contributes to the prevention of disease transmission, supporting global health efforts by minimizing the risk of introducing and spreading infectious diseases across borders. Consequently, disease exposure in specific regions serves as a crucial motivator for travellers to seek appropriate vaccinations before embarking on their international journeys.

Public Health Enhancement

• Public health enhancement is a significant opportunity arising from the promotion and utilization of travel vaccines. By encouraging widespread vaccination among travellers, there is a unique chance to bolster public health on a global scale. Travel vaccines not only protect individual travellers but also contribute to the prevention and control of infectious diseases, reducing the overall burden on healthcare systems and societies.
• The opportunity lies in creating a more resilient and robust public health infrastructure. Vaccination campaigns targeted at specific travel-related diseases can lead to a reduction in the incidence of these illnesses, preventing outbreaks and their associated societal impacts. Moreover, as individuals receive vaccinations before embarking on international journeys, the risk of introducing and spreading diseases across borders diminishes, contributing to global health security.
• Public health enhancement through travel vaccines also aligns with the principles of preventive medicine, emphasizing the importance of proactive measures to avoid illness. This approach not only improves the health outcomes of travellers but also establishes a foundation for healthier communities by reducing the transmission of infectious diseases. The opportunity to enhance public health through travel vaccines underscores the importance of investing in preventive healthcare strategies, fostering a more resilient and collectively protected global population.

Travel Vaccines Market Segment Analysis:

Travel Vaccines Market Segmented on the basis of Disease Type, Product, and Application.

By Product, Hepatitis segment is expected to dominate the market during the forecast period

• The hepatitis A segment held the largest travel vaccines market share in 2021. While the hepatitis A segment is expected to account for the largest share during the forecast period. Hepatitis is an inflammation of the liver, often caused by viral infections. There are several types of hepatitis viruses, including Hepatitis A and Hepatitis B, which are commonly associated with travel-related risks.
• Hepatitis A and B may be more prevalent in certain regions of the world, especially in areas with poor sanitation and hygiene practices. Travelers visiting these regions are at an increased risk of exposure to the viruses, making Hepatitis vaccines a crucial preventive measure.
• Hepatitis A is often transmitted through contaminated food and water. Travelers to regions with inadequate sanitation may be at a higher risk of consuming contaminated substances, making Hepatitis A vaccination essential for protection.
• Hepatitis B is primarily transmitted through contact with infected blood or bodily fluids. Travelers engaging in activities that may involve exposure to blood, such as medical procedures or risky behaviors, are at an increased risk. Hepatitis B vaccination is particularly important for healthcare workers and those involved in certain types of travel.

By Application, Outbound Travel segment held the largest share of 46.23% in 2022

• Outbound travellers often visit regions with different climates, environments, and health risks. They may encounter diseases that are not prevalent in their home countries, necessitating specific travel vaccines for protection against region-specific pathogens.
• Some countries impose mandatory vaccination requirements for entry. Travelers departing from their home countries may need to demonstrate proof of vaccination against certain diseases, such as yellow fever, to enter their destination country.
• Outbound travellers may visit countries with varying levels of healthcare infrastructure. Access to medical facilities and healthcare services can differ significantly, making preventive measures, including vaccinations, crucial for maintaining health while abroad.
• With the rise of globalization and increased international travel, more individuals are exploring destinations across borders. This trend contributes to a higher demand for travel vaccines, as people venture into regions with different disease profiles.

Travel Vaccines Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America, particularly the United States, has a well-established and robust healthcare system with high levels of healthcare spending. This contributes to the accessibility and affordability of vaccines, making them more widely available to the population.
• North American countries, including the U.S. and Canada, often have stringent travel regulations that may require specific vaccinations for entry or return. This creates a strong demand for travel vaccines among the population.
• North America is a major hub for global business and tourism. The frequent international travel of individuals for business and leisure purposes contributes to the demand for travel vaccines, as travellers seek protection against diseases prevalent in different parts of the world.
• Public health awareness and education in North America are generally high. People are more likely to seek preventive healthcare measures, including vaccinations, before traveling internationally. This proactive approach contributes to the dominance of the market.
• North America hosts several major pharmaceutical and biotech companies, research institutions, and universities that play a pivotal role in the development and distribution of vaccines. This contributes to a well-established infrastructure supporting the travel vaccines market.

Travel Vaccines Market Top Key Players:

• Pfizer (United States)
• Merck (United States)
• Abbott (United States)
• Dynavax Technologies (United States)
• Emergent BioSolutions Inc. (United States)
• Bharat Biotech (India)
• Altimmune Inc. (United States)
• Valeant Pharmaceuticals (Canada)
• Sanofi(France)
• GlaxoSmithKline (United Kingdom)
• AstraZeneca (United Kingdom)
• Janssen Pharmaceuticals (Belgium)
• Roche (Switzerland)
• Lupin (India)
• Mitsubishi Tanabe Pharma (Japan)
• LG Life Sciences / LG Chem Ltd. (South Korea)
• Novartis AG (Switzerland)
• Valneva SE (France)
• GlycoVaxyn (Switzerland)
• Takeda Pharmaceutical (Japan)
• SK Chemicals (South Korea)
• Hualan Biological Engineering (China)
• Indian Immunologicals (India)
• Beijing Minhai Biotechnology (China)
• CSL Ltd. (Australia)

Key Industry Developments in the Travel Vaccines Market:

• In December 2021, Emergent BioSolutions Inc. declared the first participant dosed in its phase 1 study, EBS-UFV-001, studying the safety, tolerability, and immunogenicity of its investigational universal influenza vaccine candidate. The current and updated version of this influenza vaccine candidate includes multiple components intended to induce broad and supra-seasonal immunity against influenza A viruses.
• In June 2021, Merck & Co., Inc. and Sanofi successfully developed the Vaxelis vaccine (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Haemophilus b Conjugate, Inactivated Poliovirus, and Hepatitis B Vaccine) as part of a US-based partnership between both the companies. The vaccine is considered as the first hexavalent combination vaccine available in the US indicated for active immunization to help prevent DTP, polio, and hepatitis B.

1. INTRODUCTION
   1. RESEARCH OBJECTIVES
   2. RESEARCH METHODOLOGY
   3. RESEARCH PROCESS
   4. SCOPE AND COVERAGE
      1. Market Definition
      2. Key Questions Answered
   5. MARKET SEGMENTATION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GROWTH OPPORTUNITIES BY SEGMENT
5. MARKET LANDSCAPE
   1. PORTER’S FIVE FORCES ANALYSIS
      1. Bargaining Power Of Supplier
      2. Threat Of New Entrants
      3. Threat Of Substitutes
      4. Competitive Rivalry
      5. Bargaining Power Among Buyers
   2. INDUSTRY VALUE CHAIN ANALYSIS
   3. MARKET DYNAMICS
      1. Drivers
      2. Restraints
      3. Opportunities
      4. Challenges
   4. MARKET TREND ANALYSIS
   5. REGULATORY LANDSCAPE
   6. PESTLE ANALYSIS
   7. PRICE TREND ANALYSIS
   8. PATENT ANALYSIS
   9. TECHNOLOGY EVALUATION
   10. MARKET IMPACT OF THE RUSSIA-UKRAINE WAR
       1. Geopolitical Market Disruptions
       2. Supply Chain Disruptions
       3. Instability in Emerging Markets
   11. ECOSYSTEM
6. TRAVEL VACCINESMARKET BY DISEASE TYPE (2016-2030)
   1. TRAVEL VACCINESMARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. COVID-19
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. EBOLA
   5. INFLUENZA
   6. HEPATITIS
7. TRAVEL VACCINESMARKET BY PRODUCT (2016-2030)
   1. TRAVEL VACCINESMARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. HEPATITIS
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. MENINGOCOCCAL VACCINES
   5. DPT
   6. TYPHOID
   7. MEASLES MUMPS & RUBELLA
   8. OTHERS
8. TRAVEL VACCINESMARKET BY APPLICATION (2016-2030)
   1. TRAVEL VACCINESMARKET SNAPSHOT AND GROWTH ENGINE
   2. MARKET OVERVIEW
   3. DOMESTIC TRAVEL
      1. Introduction And Market Overview
      2. Historic And Forecasted Market Size in Value (2016 – 2030F)
      3. Historic And Forecasted Market Size in Volume (2016 – 2030F)
      4. Key Market Trends, Growth Factors And Opportunities
      5. Geographic Segmentation Analysis
   4. OUTBOUND TRAVEL
9. COMPANY PROFILES AND COMPETITIVE ANALYSIS
   1. COMPETITIVE LANDSCAPE
      1. Competitive Positioning
      2. TRAVEL VACCINES Market Share By Manufacturer (2022)
      3. Industry BCG Matrix
      4. Heat Map Analysis
      5. Mergers & Acquisitions
   2. PFIZER (UNITED STATES)
      1. Company Overview
      2. Key Executives
      3. Company Snapshot
      4. Role of the Company in the Market
      5. Sustainability and Social Responsibility
      6. Operating Business Segments
      7. Product Portfolio
      8. Business Performance (Production Volume, Sales Volume, Sales Margin, Production Capacity, Capacity Utilization Rate)
      9. Key Strategic Moves And Recent Developments
      10. SWOT Analysis
   3. MERCK (UNITED STATES)
   4. ABBOTT (UNITED STATES)
   5. DYNAVAX TECHNOLOGIES (UNITED STATES)
   6. EMERGENT BIOSOLUTIONS INC. (UNITED STATES)
   7. BHARAT BIOTECH (INDIA)
   8. ALTIMMUNE INC. (UNITED STATES)
   9. VALEANT PHARMACEUTICALS (CANADA)
   10. SANOFI (FRANCE)
   11. GLAXOSMITHKLINE (UNITED KINGDOM)
   12. ASTRAZENECA (UNITED KINGDOM)
   13. JANSSEN PHARMACEUTICALS (BELGIUM)
   14. ROCHE (SWITZERLAND)
   15. LUPIN (INDIA)
   16. MITSUBISHI TANABE PHARMA (JAPAN)
   17. LG LIFE SCIENCES / LG CHEM LTD. (SOUTH KOREA)
   18. NOVARTIS AG (SWITZERLAND)
   19. VALNEVA SE (FRANCE)
   20. GLYCOVAXYN (SWITZERLAND)
   21. TAKEDA PHARMACEUTICAL (JAPAN)
   22. SK CHEMICALS (SOUTH KOREA)
   23. HUALAN BIOLOGICAL ENGINEERING (CHINA)
   24. INDIAN IMMUNOLOGICALS (INDIA)
   25. BEIJING MINHAI BIOTECHNOLOGY (CHINA)
   26. CSL LTD. (AUSTRALIA)
10. GLOBAL TRAVEL VACCINESMARKET BY REGION
    1. OVERVIEW
    2. NORTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Disease Type
       4. Historic And Forecasted Market Size By Product
       5. Historic And Forecasted Market Size By Application
       6. Historic And Forecasted Market Size By Country
          1. USA
          2. Canada
          3. Mexico
    3. EASTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Russia
          2. Bulgaria
          3. The Czech Republic
          4. Hungary
          5. Poland
          6. Romania
          7. Rest Of Eastern Europe
    4. WESTERN EUROPE
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Germany
          2. United Kingdom
          3. France
          4. The Netherlands
          5. Italy
          6. Spain
          7. Rest Of Western Europe
    5. ASIA PACIFIC
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. China
          2. India
          3. Japan
          4. South Korea
          5. Malaysia
          6. Thailand
          7. Vietnam
          8. The Philippines
          9. Australia
          10. New-Zealand
          11. Rest Of APAC
    6. MIDDLE EAST & AFRICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Turkey
          2. Bahrain
          3. Kuwait
          4. Saudi Arabia
          5. Qatar
          6. UAE
          7. Israel
          8. South Africa
    7. SOUTH AMERICA
       1. Key Market Trends, Growth Factors And Opportunities
       2. Key Manufacturers
       3. Historic And Forecasted Market Size By Segments
       4. Historic And Forecasted Market Size By Country
          1. Brazil
          2. Argentina
          3. Rest of South America
11. INVESTMENT ANALYSIS
12. ANALYST VIEWPOINT AND CONCLUSION
    1. Recommendations and Concluding Analysis
    2. Potential Market Strategies

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. TRAVEL VACCINES MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. TRAVEL VACCINES MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. TRAVEL VACCINES MARKET COMPETITIVE RIVALRY
TABLE 005. TRAVEL VACCINES MARKET THREAT OF NEW ENTRANTS
TABLE 006. TRAVEL VACCINES MARKET THREAT OF SUBSTITUTES
TABLE 007. TRAVEL VACCINES MARKET BY TYPE
TABLE 008. MONO VACCINES MARKET OVERVIEW (2016-2028)
TABLE 009. COMBINATION VACCINES MARKET OVERVIEW (2016-2028)
TABLE 010. OTHERS MARKET OVERVIEW (2016-2028)
TABLE 011. TRAVEL VACCINES MARKET BY APPLICATION
TABLE 012. DOMESTIC TRAVEL MARKET OVERVIEW (2016-2028)
TABLE 013. OUTBOUND TRAVEL MARKET OVERVIEW (2016-2028)
TABLE 014. OTHER MARKET OVERVIEW (2016-2028)
TABLE 015. NORTH AMERICA TRAVEL VACCINES MARKET, BY TYPE (2016-2028)
TABLE 016. NORTH AMERICA TRAVEL VACCINES MARKET, BY APPLICATION (2016-2028)
TABLE 017. N TRAVEL VACCINES MARKET, BY COUNTRY (2016-2028)
TABLE 018. EUROPE TRAVEL VACCINES MARKET, BY TYPE (2016-2028)
TABLE 019. EUROPE TRAVEL VACCINES MARKET, BY APPLICATION (2016-2028)
TABLE 020. TRAVEL VACCINES MARKET, BY COUNTRY (2016-2028)
TABLE 021. ASIA PACIFIC TRAVEL VACCINES MARKET, BY TYPE (2016-2028)
TABLE 022. ASIA PACIFIC TRAVEL VACCINES MARKET, BY APPLICATION (2016-2028)
TABLE 023. TRAVEL VACCINES MARKET, BY COUNTRY (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET, BY TYPE (2016-2028)
TABLE 025. MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET, BY APPLICATION (2016-2028)
TABLE 026. TRAVEL VACCINES MARKET, BY COUNTRY (2016-2028)
TABLE 027. SOUTH AMERICA TRAVEL VACCINES MARKET, BY TYPE (2016-2028)
TABLE 028. SOUTH AMERICA TRAVEL VACCINES MARKET, BY APPLICATION (2016-2028)
TABLE 029. TRAVEL VACCINES MARKET, BY COUNTRY (2016-2028)
TABLE 030. PFIZER: SNAPSHOT
TABLE 031. PFIZER: BUSINESS PERFORMANCE
TABLE 032. PFIZER: PRODUCT PORTFOLIO
TABLE 033. PFIZER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 033. SANOFI: SNAPSHOT
TABLE 034. SANOFI: BUSINESS PERFORMANCE
TABLE 035. SANOFI: PRODUCT PORTFOLIO
TABLE 036. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 036. GLAXOSMITHKLINE: SNAPSHOT
TABLE 037. GLAXOSMITHKLINE: BUSINESS PERFORMANCE
TABLE 038. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
TABLE 039. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 039. MERCK: SNAPSHOT
TABLE 040. MERCK: BUSINESS PERFORMANCE
TABLE 041. MERCK: PRODUCT PORTFOLIO
TABLE 042. MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 042. ASTRAZENECA: SNAPSHOT
TABLE 043. ASTRAZENECA: BUSINESS PERFORMANCE
TABLE 044. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 045. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 045. JANSSEN PHARMACEUTICALS: SNAPSHOT
TABLE 046. JANSSEN PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 047. JANSSEN PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 048. JANSSEN PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 048. ABBOTT: SNAPSHOT
TABLE 049. ABBOTT: BUSINESS PERFORMANCE
TABLE 050. ABBOTT: PRODUCT PORTFOLIO
TABLE 051. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 051. MITSUBISHI TANABE PHARMA: SNAPSHOT
TABLE 052. MITSUBISHI TANABE PHARMA: BUSINESS PERFORMANCE
TABLE 053. MITSUBISHI TANABE PHARMA: PRODUCT PORTFOLIO
TABLE 054. MITSUBISHI TANABE PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 054. LG LIFE SCIENCES: SNAPSHOT
TABLE 055. LG LIFE SCIENCES: BUSINESS PERFORMANCE
TABLE 056. LG LIFE SCIENCES: PRODUCT PORTFOLIO
TABLE 057. LG LIFE SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 057. ROCHE: SNAPSHOT
TABLE 058. ROCHE: BUSINESS PERFORMANCE
TABLE 059. ROCHE: PRODUCT PORTFOLIO
TABLE 060. ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 060. LUPIN: SNAPSHOT
TABLE 061. LUPIN: BUSINESS PERFORMANCE
TABLE 062. LUPIN: PRODUCT PORTFOLIO
TABLE 063. LUPIN: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 063. TAKEDA PHARMACEUTICAL: SNAPSHOT
TABLE 064. TAKEDA PHARMACEUTICAL: BUSINESS PERFORMANCE
TABLE 065. TAKEDA PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 066. TAKEDA PHARMACEUTICAL: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 066. VALEANT PHARMACEUTICALS: SNAPSHOT
TABLE 067. VALEANT PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 068. VALEANT PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 069. VALEANT PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 069. SK CHEMICALS: SNAPSHOT
TABLE 070. SK CHEMICALS: BUSINESS PERFORMANCE
TABLE 071. SK CHEMICALS: PRODUCT PORTFOLIO
TABLE 072. SK CHEMICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 072. HUALAN BIOLOGICAL ENGINEERING: SNAPSHOT
TABLE 073. HUALAN BIOLOGICAL ENGINEERING: BUSINESS PERFORMANCE
TABLE 074. HUALAN BIOLOGICAL ENGINEERING: PRODUCT PORTFOLIO
TABLE 075. HUALAN BIOLOGICAL ENGINEERING: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. TRAVEL VACCINES MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. TRAVEL VACCINES MARKET OVERVIEW BY TYPE
FIGURE 012. MONO VACCINES MARKET OVERVIEW (2016-2028)
FIGURE 013. COMBINATION VACCINES MARKET OVERVIEW (2016-2028)
FIGURE 014. OTHERS MARKET OVERVIEW (2016-2028)
FIGURE 015. TRAVEL VACCINES MARKET OVERVIEW BY APPLICATION
FIGURE 016. DOMESTIC TRAVEL MARKET OVERVIEW (2016-2028)
FIGURE 017. OUTBOUND TRAVEL MARKET OVERVIEW (2016-2028)
FIGURE 018. OTHER MARKET OVERVIEW (2016-2028)
FIGURE 019. NORTH AMERICA TRAVEL VACCINES MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. EUROPE TRAVEL VACCINES MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. ASIA PACIFIC TRAVEL VACCINES MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 023. SOUTH AMERICA TRAVEL VACCINES MARKET OVERVIEW BY COUNTRY (2016-2028)